Recent Analysts’ Ratings Updates for Bausch Health Cos (BHC)

A number of research firms have changed their ratings and price targets for Bausch Health Cos (NYSE: BHC):

• 11/5/2026 – Bausch Health Cos was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/29/2026 – Bausch Health Cos had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 10/29/2026 – Bausch Health Cos had its price target raised by Jefferies Financial Group from $6.50 to $8.00. They now have a “hold” rating on the stock.
• 10/29/2026 – Bausch Health Cos had its price target raised by Royal Bank Of Canada from $9.00 to $10.00. They now have a “sector perform” rating on the stock.
• 10/8/2026 – Bausch Health Cos had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $9.00 price target on the stock.
• 9/21/2026 – Bausch Health Cos was upgraded by Zacks Research from “hold” to “strong-buy”.

Bausch Health Cos Trading Down 1.3%

NYSE BHC traded down $0.10 on Tuesday, hitting $8.29. 906,589 shares of the company traded hands, compared to its average volume of 2,694,230. The business’s 50 day moving average price is $6.44 and its 200-day moving average price is $5.75. Bausch Health Cos Inc. has a 52-week low of $4.33 and a 52-week high of $9.04. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -3.62 and a beta of 0.30.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 EPS for the quarter, topping the consensus estimate of $1.25 by $0.52. The firm had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%. As a group, sell-side analysts predict that Bausch Health Cos Inc. will post 4.53 earnings per share for the current year.

Insider Buying and Selling at Bausch Health Cos

In related news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.